PreciseDx will leverage $20.7m in new funding to accelerate validation testing for PreciseBreast, an artificial intelligence (AI)- powered test that analyzes breast cancer cell morphology to predict 6-year risk of recurrence in early-stage breast cancer patients.
Massachusetts-based investment adviser Eventide Asset Management led the series B funding round, PreciseDx announced on 21 August. Other participants included...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?